Objective Dynamic detection of urinary Livin mRNA expression in patients with bladder cancer before and after operation and its clinical value in early diagnosis of bladder cancer. Methods Urine of 30 patients with initially diagnosed BTCC was collected before operation and one week, one month, three months, six months and 18 months after operation. Urine of 30 healthy volunteers and 30 Non-urological cancer patients was collected. Expression of survivin mRNA in urine exfoliated cells was detected by real-time PCR. Results Livin mRNA was highly expressed in the urine of 30 patients before operation, and the relative copy number was (96.33±35.79), and the expression level increased with the clinical stage and grade of the tumor from low to high; 2 of 30 patients in the control group showed high expression, the relative copy number was 43.17 and 47.52, the other was low expression, and the expression level was low. The copy number was (16.25±7.81); 30 cases in normal group were low expression, and the relative copy number was (13.74±1.57). The expression of Livin mRNA in urine of the case group was significantly higher than that of the control group and the normal group (P<0.05); the expression of Livin mRNA in urine of the case group was significantly lower than that of the control group (P<0.05); the expression of Livin mRNA in urine of the case group was significantly lower than that of the normal group (P<0.05); there was no significant difference between the control group and the normal group (P>0.05). Follow-up to 18 months after surgery, 5 patients with recurrence before reoperation (98.27±26.55) and 6 months after the initial operation were significantly different (P<0.05). Conclusion Dynamic detection of urinary Livin mRNA expression with high specificity and sensitivity can be used as an important noninvasive marker for early diagnosis of bladder cancer.

Objective To observe the safety of high-dose vitamin C intravenous infusion in the treatment of advanced malignant tumors, and to provide reference for clinical rational use of vitamin C. Methods from April 2016 to June 2017, 21 patients with advanced malignant tumor were treated with high dose vitamin C in aviation general hospital, chinese medical sciences university. The symptoms of nausea, loss of appetite, abdominal distention, diarrhea, abdominal pain, dizziness, blood glucose, electrolytes (blood Na+, K+, Cl-) and liver and kidney function (alanine aminotransferase, aspartate aminotransferase, total bilirubin, urea, creatinine and Uric acid) were recorded in 21 patients with tumor before and after high dose vitamin C treatment. The paired test was then used to compare these patients' clinical symptoms and blood biochemical parameters after high-dose vitamin C treatment. Results there were no significant changes in blood glucose, electrolytes, liver and kidney function in patients with malignant tumor treated with high dose vitamin C intravenous drip. One patient complained of loss of appetite, one patient complained of nausea and abdominal distention, and one patient suffered from lower limb edema. However, no similar symptoms and manifestations were found when vitamin C was used again, and no diarrhea, abdominal pain, dizziness and other symptoms was observed. Conclusions High-dose vitamin C has not been found in the treatment of advanced malignant tumor patients with adverse reactions and the security is good.